• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管紧张素转换酶抑制剂相关的上气道血管性水肿发生率增加。

Increasing rate of angiotensin-converting enzyme inhibitor-related upper airway angio-oedema.

作者信息

Holm Jonas Peter Yde, Ovesen Therese

机构信息

Øre- næse- og halsafdelingen, Aarhus Universitetshospital, 8000 Aarhus C, Denmark.

出版信息

Dan Med J. 2012 Jun;59(6):A4449.

PMID:22677247
Abstract

INTRODUCTION

The objective of this study was to evaluate whether the increased use of angiotensin-converting enzyme inhibitors (ACEI) has affected the rate of upper airway angio-oedema (AE). In addition, we evaluated the presentation and treatment of patients with upper airway AE.

MATERIAL AND METHODS

This was a ten-year retrospective study of 112 patients presenting with upper airway AE at The Department of Otorhinolaryngology, Aarhus University Hospital, Denmark. Incidence, presentation and treatment in the 2000-2004-period were compared to those of the 2005-2009-period.

RESULTS

In the ten-year period, we found 112 AE patients of whom 39% were using ACEI. The relative risk of AE was 7.7 (p < 0.0001) among ACEI users. We found a 67% increase in AE in 2005-2009 compared with 2000-2004 which corresponds to a similar increase in ACEI use in the Danish population. The most frequent anatomic sites of involvement were the floor of the mouth and/or oropharynx including the base of the tongue. Two patients required intubation upon their arrival to the hospital. None progressed in airway obstruction requiring intubation later. None died.

CONCLUSION

We found an increasing rate of ACEI-related upper airway AE over a ten-year period corresponding to greater use of ACEI in the population. With a relative risk of 7.7 and continuously increasing ACEI consumption, this condition will certainly require future attention and resources as almost one third of patients are admitted to an intensive care unit.

摘要

引言

本研究的目的是评估血管紧张素转换酶抑制剂(ACEI)使用的增加是否影响了上气道血管性水肿(AE)的发生率。此外,我们评估了上气道AE患者的临床表现和治疗情况。

材料与方法

这是一项对丹麦奥胡斯大学医院耳鼻喉科112例上气道AE患者进行的为期十年的回顾性研究。将2000 - 2004年期间的发病率、临床表现和治疗情况与2005 - 2009年期间进行比较。

结果

在这十年期间,我们发现112例AE患者,其中39%正在使用ACEI。ACEI使用者发生AE的相对风险为7.7(p < 0.0001)。与2000 - 2004年相比,2005 - 2009年AE增加了67%,这与丹麦人群中ACEI使用的类似增加相对应。最常受累的解剖部位是口腔底部和/或口咽,包括舌根。两名患者入院时需要插管。没有患者随后出现需要插管的气道梗阻进展。无人死亡。

结论

我们发现在十年期间,与ACEI相关的上气道AE发生率不断上升,这与人群中ACEI使用的增加相对应。由于相对风险为7.7且ACEI的消费量持续增加,这种情况肯定需要未来的关注和资源投入,因为几乎三分之一的患者需要入住重症监护病房。

相似文献

1
Increasing rate of angiotensin-converting enzyme inhibitor-related upper airway angio-oedema.血管紧张素转换酶抑制剂相关的上气道血管性水肿发生率增加。
Dan Med J. 2012 Jun;59(6):A4449.
2
Management of angiotensin-converting enzyme inhibitor-induced angioedema.血管紧张素转化酶抑制剂引起的血管性水肿的治疗。
Laryngoscope. 2011 Nov;121(11):2327-34. doi: 10.1002/lary.22349.
3
Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema.血管紧张素转换酶抑制剂所致血管性水肿的临床经验
Otolaryngol Head Neck Surg. 2007 Dec;137(6):931-5. doi: 10.1016/j.otohns.2007.08.012.
4
Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management.血管紧张素转换酶抑制剂所致血管性水肿:一项多中心综述及气道管理算法
Ann Otol Rhinol Laryngol. 2001 Sep;110(9):834-40. doi: 10.1177/000348940111000906.
5
Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department.对因血管紧张素转换酶抑制剂诱发血管性水肿而前往急诊科就诊的患者进行的多中心研究。
Ann Allergy Asthma Immunol. 2008 Apr;100(4):327-32. doi: 10.1016/S1081-1206(10)60594-7.
6
Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.血管紧张素转换酶抑制剂和血管紧张素II受体拮抗剂。
Arch Otolaryngol Head Neck Surg. 2004 Dec;130(12):1416-9. doi: 10.1001/archotol.130.12.1416.
7
Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema.血管紧张素转换酶(ACE)抑制剂与血管性水肿
Br J Dermatol. 1997 Feb;136(2):153-8.
8
ACEI associated angioedema - a case study and review.血管紧张素转换酶抑制剂相关性血管性水肿——病例研究与综述
Aust Fam Physician. 2011 Dec;40(12):985-8.
9
Delayed presentation of ACE inhibitor-induced angio-oedema.血管紧张素转换酶抑制剂诱发的血管性水肿延迟表现
BMJ Case Rep. 2013 Jul 29;2013:bcr2013010453. doi: 10.1136/bcr-2013-010453.
10
Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema.C1酯酶抑制剂在血管紧张素转换酶抑制剂所致血管性水肿中的作用。
Laryngoscope. 2015 Jun;125(6):E198-202. doi: 10.1002/lary.25113. Epub 2015 Jan 13.

引用本文的文献

1
Bradykinin-Mediated Angioedema Induced by Drugs.药物诱导的缓激肽介导的血管性水肿
J Clin Med. 2025 Aug 12;14(16):5712. doi: 10.3390/jcm14165712.
2
Angioedema without wheals: a clinical update.无风团性血管性水肿:临床更新。
Balkan Med J. 2021 Mar;38(2):73-81. doi: 10.5152/balkanmedj.2021.20060.
3
Clinical Features and Disease Course of Primary Angioedema Patients in a Tertiary Care Hospital.三级护理医院中原发性血管性水肿患者的临床特征与病程
J Asthma Allergy. 2020 Jul 17;13:225-236. doi: 10.2147/JAA.S245161. eCollection 2020.
4
ACE-Inhibitor Related Angioedema Is Not Sufficiently Reported to the Danish Adverse Drug Reactions Database.与血管紧张素转换酶抑制剂相关的血管性水肿未充分上报至丹麦药品不良反应数据库。
Drug Healthc Patient Saf. 2019 Dec 16;11:105-113. doi: 10.2147/DHPS.S205119. eCollection 2019.
5
Evaluation and Management of Angioedema in the Emergency Department.急诊科血管性水肿的评估与管理。
West J Emerg Med. 2019 Jul;20(4):587-600. doi: 10.5811/westjem.2019.5.42650. Epub 2019 Jul 2.
6
Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.迟发性血管紧张素转换酶抑制剂诱发血管性水肿的致命结局:一例报告
Medicine (Baltimore). 2018 Aug;97(31):e11695. doi: 10.1097/MD.0000000000011695.
7
Angioedema in the emergency department: a practical guide to differential diagnosis and management.急诊科血管性水肿:鉴别诊断与管理实用指南
Int J Emerg Med. 2017 Dec;10(1):15. doi: 10.1186/s12245-017-0141-z. Epub 2017 Apr 13.
8
Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.105例血管紧张素转换酶抑制剂诱发血管性水肿患者的评估
Int J Otolaryngol. 2017;2017:1476402. doi: 10.1155/2017/1476402. Epub 2017 Feb 14.
9
Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV.与二肽基肽酶IV药理抑制相关的复发性血管性水肿
BMJ Case Rep. 2017 Jan 10;2017:bcr2016217802. doi: 10.1136/bcr-2016-217802.
10
The Use of Plasma-Derived Complement C1-Esterase Inhibitor Concentrate (Berinert®) in the Treatment of Angiotensin Converting Enzyme-Inhibitor Related Angioedema.血浆源性补体C1酯酶抑制剂浓缩物(百林妥®)在治疗血管紧张素转换酶抑制剂相关血管性水肿中的应用
Case Rep Emerg Med. 2016;2016:3930923. doi: 10.1155/2016/3930923. Epub 2016 Mar 31.